Crossover to PDT after the unsuccessful micropulse laser treatment of central serous chorioretinopathy

Maciej Gawęcki , Krzysztof Kiciński , Andrzej Grzybowski
{"title":"Crossover to PDT after the unsuccessful micropulse laser treatment of central serous chorioretinopathy","authors":"Maciej Gawęcki ,&nbsp;Krzysztof Kiciński ,&nbsp;Andrzej Grzybowski","doi":"10.1016/j.aopr.2024.01.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Subthreshold micropulse laser (SML) and photodynamic therapy (PDT) are among the most effective therapeutic modalities applied to central serous chorioretinopathy (CSCR). This study aimed to evaluate the efficacy and durability of PDT in CSCR cases unresponsive to at least two SML treatments.</p></div><div><h3>Methods</h3><p>The study included 26 consecutive eyes of 24 patients (21 males and three females) with chronic CSCR. In all cases, a lack of reduction in subretinal fluid (SRF) levels was noted after at least two consecutive SML sessions. The parameters of best corrected visual acuity (BCVA) and spectral domain optical coherence tomography (SD-OCT) were evaluated at baseline and 1, 3 and 12 months post-PDT.</p></div><div><h3>Results</h3><p>The mean duration of symptoms in the group was 53.81 ± 39.48 months, the mean age of the patients was 49.26 ± 12.91 years, and the mean subfoveal choroidal thickness (SFCT) was 572.11 ± 116.21 mm. Complete resorption of SRF was observed in 21 out of 26 eyes (80.77%) at 1 month and sustained in 18 cases (69.23%) at 12 months. At 12 months, in the sustained group, BCVA improved significantly from 0.39 ± 0.18 to 0.19 ± 0.2 logMAR (<em>P</em> = 0.01), central subfoveal thickness (CST) reduced from 316.44 ± 75.83 mm to 197.67 ± 22.99 mm (<em>P</em> &lt; 0.0001), and SFCT reduced from 579.28 mm to 446.78 mm (<em>P</em> &lt; 0.0001).</p></div><div><h3>Conclusions</h3><p>PDT provides the opportunity for the successful treatment of CSCR unresponsive to SML treatment. Improvements are possible even in cases with a long duration of symptoms and significant alterations in retinal morphology. Thus, PDT should be considered for patients with prominently increased choroidal thickness.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667376224000040/pdfft?md5=d6e2139d9e4970a2e57c228e7f858403&pid=1-s2.0-S2667376224000040-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in ophthalmology practice and research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667376224000040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

Subthreshold micropulse laser (SML) and photodynamic therapy (PDT) are among the most effective therapeutic modalities applied to central serous chorioretinopathy (CSCR). This study aimed to evaluate the efficacy and durability of PDT in CSCR cases unresponsive to at least two SML treatments.

Methods

The study included 26 consecutive eyes of 24 patients (21 males and three females) with chronic CSCR. In all cases, a lack of reduction in subretinal fluid (SRF) levels was noted after at least two consecutive SML sessions. The parameters of best corrected visual acuity (BCVA) and spectral domain optical coherence tomography (SD-OCT) were evaluated at baseline and 1, 3 and 12 months post-PDT.

Results

The mean duration of symptoms in the group was 53.81 ± 39.48 months, the mean age of the patients was 49.26 ± 12.91 years, and the mean subfoveal choroidal thickness (SFCT) was 572.11 ± 116.21 mm. Complete resorption of SRF was observed in 21 out of 26 eyes (80.77%) at 1 month and sustained in 18 cases (69.23%) at 12 months. At 12 months, in the sustained group, BCVA improved significantly from 0.39 ± 0.18 to 0.19 ± 0.2 logMAR (P = 0.01), central subfoveal thickness (CST) reduced from 316.44 ± 75.83 mm to 197.67 ± 22.99 mm (P < 0.0001), and SFCT reduced from 579.28 mm to 446.78 mm (P < 0.0001).

Conclusions

PDT provides the opportunity for the successful treatment of CSCR unresponsive to SML treatment. Improvements are possible even in cases with a long duration of symptoms and significant alterations in retinal morphology. Thus, PDT should be considered for patients with prominently increased choroidal thickness.

微脉冲激光治疗中心性浆液性脉络膜视网膜病变失败后转用光导疗法
目的阈下微脉冲激光(SML)和光动力疗法(PDT)是治疗中心性浆液性脉络膜视网膜病变(CSCR)最有效的治疗方法之一。本研究旨在评估光动力疗法对至少两次 SML 治疗无效的 CSCR 病例的疗效和持久性。在所有病例中,经过至少两次连续的 SML 治疗后,视网膜下积液(SRF)水平均未下降。结果该组患者的平均病程为(53.81±39.48)个月,平均年龄为(49.26±12.91)岁,平均视网膜下脉络膜厚度(SFCT)为(572.11±116.21)毫米。26只眼睛中有21只(80.77%)在1个月时观察到SRF完全吸收,18只(69.23%)在12个月时观察到SRF持续吸收。12 个月时,持续组的 BCVA 从 0.39 ± 0.18 显著改善到 0.19 ± 0.2 logMAR(P = 0.01),中央眼底厚度(CST)从 316.44 ± 75.83 mm 减少到 197.结论PDT为成功治疗对SML治疗无反应的CSCR提供了机会。即使是症状持续时间较长、视网膜形态发生显著改变的病例,也有可能获得改善。因此,脉络膜厚度明显增加的患者应考虑使用 PDT。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
0
审稿时长
66 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信